Thermo Fisher Scientific Inc. (TMO)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Thermo Fisher as a quality business with a broad set of laboratory tools, recurring consumables, and global scale that smaller rivals cannot easily copy. The filed figures show fiscal Q2 2026, the quarter ended 2026-06-27, had revenue of $12.0B, net income of $1.7B, and diluted EPS of $4.68, compared with fiscal Q2 2025, the quarter ended 2025-06-28, at $10.9B, $1.6B, and $4.28. That is real progress. For FY2025, the year ended 2025-12-31, revenue was $44.6B, net income $6.7B, and diluted EPS $17.74, up from FY2024, the year ended 2024-12-31, at $42.9B, $6.3B, and $16.53. The balance sheet looks sound: FairStock calculates a Piotroski F-Score of 9/9 and an Altman Z-Score of 3.46. However, FairStock classifies it as a SLOW GROWER because profit grew only 1.0% a year over five years, while revenue grew 6.7%. Returns are less exciting: FairStock shows ROE of 13.51% and ROCE of 5.13%, with debt-to-equity of 0.81. At the 2026-10-13 close of $663.04, FairStock calculates a P/E of 35.70, a PEG of 4.85, EV/EBITDA of 23.55, and an FCF yield of 3.0% on $7.3B trailing free cash flow. The Graham Number is $243.99, implying a margin of safety of -171.75%. So the business is sturdy, but the price already assumes a lot. I prefer wonderful businesses at fair prices; here the price appears full, and the five-year growth record does not support the multiple.

In plain English: Thermo Fisher Scientific sells laboratory equipment, scientific instruments, and services used in healthcare research and drug development. The business looks financially strong, with rising sales and profits and solid signs of financial health. But the stock price looks expensive compared with the company's earnings, cash flow, and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-27) · fiscal Q1 2026 10-Q (period ended 2026-03-28) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer